# GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers

> **NCT00488566** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 50 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** GSK drug
- **OTHER:** Placebo
- **OTHER:** Lamictal

## Key facts

- **NCT ID:** NCT00488566
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-31
- **Primary completion:** 2008-05-31
- **Final completion:** 2008-05-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488566, "GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00488566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*